Vaccines News and Research RSS Feed - Vaccines News and Research

SP Scientific Announces Spring Lyophilization Program

SP Scientific has announced its program of events for April 2015 will focus on the latest advances in lyophilization and freeze drying. [More]

Nanolek, Green Cross sign strategic deal to commercialize biologics in the Russian market

Green Cross, a South Korean biopharmaceutical company, and Nanolek, a Russian pharmaceutical company, today announced that they have entered into a strategic partnership agreement for the commercialisation of Green Cross' biologics in the Russian market. [More]

TB Alliance, U.S. Fund for UNICEF partner to bring new TB treatments for children

TB Alliance has announced a new partnership with the U.S. Fund for UNICEF that will dramatically increase the scope and impact of child and maternal health programs around the world to include the diagnosis and treatment of pediatric tuberculosis (TB), a significant cause of child mortality. [More]
Theravectys gets authorization to produce lentiviral vectors for clinical use and CAR-T cell-based immunotherapy

Theravectys gets authorization to produce lentiviral vectors for clinical use and CAR-T cell-based immunotherapy

THERAVECTYS, a clinical development biotechnology company that focuses on the development of therapeutic vaccines and immunotherapies, proudly announces that its manufacturing plant has obtained the status of a pharmaceutical manufacturing establishment, granted by the French National Agency for Medicines and Health Products Safety. [More]
Accelovance named finalist for Best Contract Research Organization at ViE Awards

Accelovance named finalist for Best Contract Research Organization at ViE Awards

Accelovance, a therapeutically focused contract research organization (CRO), has been named a finalist for "Best Contract Research Organization" at the upcoming Vaccine Industry Excellence (ViE) Awards hosted by the World Vaccine Congress. [More]
FDA approves Quadracel vaccine to protect young children from life-threatening diseases

FDA approves Quadracel vaccine to protect young children from life-threatening diseases

Sanofi Pasteur, the vaccines division of Sanofi, announced today that the U.S. Food and Drug Administration has approved use of Quadracel (Diphtheria and Tetanus Toxoids and Acellular Pertussis Absorbed and Inactivated Poliovirus; DTaP-IPV) vaccine for active immunization against diphtheria, tetanus, pertussis and poliomyelitis in children 4 through 6 years of age. [More]
CMV-based vaccine provides long-lasting protective immunity against Ebola virus

CMV-based vaccine provides long-lasting protective immunity against Ebola virus

A cytomegalovirus (CMV)-based vaccine provides long-lasting protective immunity against Ebola virus, and has potential for development as a disseminating vaccine strategy to prevent ebolavirus infection of wild African ape populations. [More]
Norovirus vaccine may be available in the future

Norovirus vaccine may be available in the future

A multivalent candidate vaccine elicits broad antibody responses to a range of norovirus strains, including strains not included in the vaccine or previously encountered by participants, according to a new study published this week in PLOS Medicine. [More]
Experimental drug that attacks brain tumor cells passes early tests

Experimental drug that attacks brain tumor cells passes early tests

An experimental drug that attacks brain tumor tissue by crippling the cells' energy source called the mitochondria has passed early tests in animal models and human tissue cultures, say Houston Methodist scientists. [More]

The fight continues to end tuberculosis

Today is World TB Day. The Centenary Institute is one of the leading medical research institutes in Australia championing the fight to put an end to this insidious disease. [More]
GenVec reports record financial results for Q4 and fiscal year 2014

GenVec reports record financial results for Q4 and fiscal year 2014

GenVec, Inc. today reported financial results for the fourth quarter and year ended December 31, 2014. For the year ended December 31, 2014, the company reported a net loss of $2.5 million, or $0.16 per share, compared with a net loss of $10.0 million, or $0.77 per share, for the year ended December 31, 2013. [More]
Scientists identify key molecules that trigger immune system to fight tularemia

Scientists identify key molecules that trigger immune system to fight tularemia

Research led by scientists at St. Jude Children's Research Hospital has identified key molecules that trigger the immune system to launch an attack on the bacterium that causes tularemia. [More]
Co-infection reduces severity of East Coast fever, can help curb human malaria

Co-infection reduces severity of East Coast fever, can help curb human malaria

When calves are infected by two parasite species at the same time, one parasite renders the other far less deadly, according to a new study published in the current journal of Science Advances. [More]
GenVec collaborates with TheraBiologics to develop NSC-mediated cancer therapeutics

GenVec collaborates with TheraBiologics to develop NSC-mediated cancer therapeutics

GenVec, Inc. today announced that it has formed a collaboration with TheraBiologics to develop cancer therapeutics leveraging both GenVec's proprietary gene delivery platform and TheraBiologics' proprietary neural stem cell (NSC) technology. [More]
Globavir, BioManguinhos partner to jointly evaluate PanGlob RT-PCR Dengue diagnostic assay

Globavir, BioManguinhos partner to jointly evaluate PanGlob RT-PCR Dengue diagnostic assay

Globavir Biosciences, Inc., a biotechnology company developing diagnostic and therapeutic technologies to treat infectious diseases, has announced a partnership with BioManguinhos, a division of the Oswaldo Cruz Foundation, for a joint evaluation of Globavir's PanGlob RT-PCR Dengue diagnostic assay. [More]
WHO calls for intensification of routine immunization services in all Ebola-affected areas

WHO calls for intensification of routine immunization services in all Ebola-affected areas

A growing risk of outbreaks of measles, pertussis, and other vaccine-preventable diseases in countries affected by Ebola must be countered by urgent scaling up of routine immunization activities, according to the World Health Organization. [More]
Cosentyx (secukinumab) safe, effective for treating psoriasis patients

Cosentyx (secukinumab) safe, effective for treating psoriasis patients

Novartis today announced new two-year results demonstrating sustained efficacy with Cosentyx (secukinumab) with an acceptable safety profile for the treatment of psoriasis patients. The data comes from the extension study of the pivotal Phase III FIXTURE and ERASURE trials. [More]
Researchers find way to enhance effects of immunotherapy in glioblastoma

Researchers find way to enhance effects of immunotherapy in glioblastoma

When cancer strikes, it may be possible for patients to fight back with their own defenses, using a strategy known as immunotherapy. According to a new study published in Nature, researchers have found a way to enhance the effects of this therapeutic approach in glioblastoma, a deadly type of brain cancer, and possibly improve patient outcomes. [More]
Austrian Centre of Industrial Biotechnology develops method to reduce production costs of valuable drugs

Austrian Centre of Industrial Biotechnology develops method to reduce production costs of valuable drugs

Imagine a loved relative suffering from cancer - and you could not afford a treatment because the drugs are too expensive. The Austrian Centre of Industrial Biotechnology (acib) developed a method with the power to reduce production costs of highly valued drugs significantly. [More]
Janssen Pharmaceutical to invest $10 million in global Dementia Discovery Fund

Janssen Pharmaceutical to invest $10 million in global Dementia Discovery Fund

Johnson & Johnson today announced that its Janssen Pharmaceutical Companies will invest $10 million in a new UK government-led global dementia discovery fund that will support innovative research to help find new ways to prevent and treat dementia and Alzheimer's disease. [More]
Advertisement
Advertisement